Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/49723
|Title:||Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes||Authors:||D'Alessio, David
Häring, H. U.
de Pablos-Velasco, P.
Dain, M. P.
|Issue Date:||2015||Publisher:||1462-8902||Journal:||Diabetes, Obesity and Metabolism||Abstract:||AimTo compare safety and efficacy of insulin glargine and liraglutide in patients with type 2 diabetes (T2DM).MethodsThis randomized, multinational, open-label trial included subjects treated for T2DM with metforminsulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%. Subjects were assigned to 24weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8mg daily. The trial was powered to detect superiority of glargine over liraglutide in percentage of people reaching HbA1c <7%.ResultsThe mean [standard deviation (s.d.)] age of the participants was 57 (9)years, the duration of diabetes was 9 (6)years, body mass index was 31.9 (4.2)kg/m(2) and HbA1c level was 9.0 (1.1)%. Equal numbers (n=489) were allocated to glargine and liraglutide. Similar numbers of subjects in both groups attained an HbA1c level of <7% (48.4 vs. 45.9%); therefore, superiority of glargine over liraglutide was not observed (p=0.44). Subjects treated with glargine had greater reductions of HbA1c [-1.94% (0.05) and -1.79% (0.05); p=0.019] and fasting plasma glucose [6.2 (1.6) and 7.9 (2.2) mmol/L; p<0.001] than those receiving liraglutide. The liraglutide group reported a greater number of gastrointestinal treatment-emergent adverse events (p<0.001). The mean (s.d.) weight change was +2.0 (4.0)kg for glargine and -3.0 (3.6)kg for liraglutide (p<0.001). Symptomatic hypoglycaemia was more common with glargine (p<0.001). A greater number of subjects in the liraglutide arm withdrew as a result of adverse events (p<0.001).ConclusionAdding either insulin glargine or liraglutide to subjects with poorly controlled T2DM reduces HbA1c substantially, with nearly half of subjects reaching target levels of 7%.||URI:||http://hdl.handle.net/10553/49723||ISSN:||1462-8902||DOI:||10.1111/dom.12406||Source:||Diabetes, Obesity and Metabolism[ISSN 1462-8902],v. 17, p. 170-178|
|Appears in Collections:||Artículos|
checked on May 31, 2020
WEB OF SCIENCETM
checked on May 31, 2020
checked on Jun 2, 2020
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.